Literature DB >> 27122778

Predictive Value of Elevated Uric Acid in Turkish Patients Undergoing Primary Angioplasty for ST Elevation Myocardial Infarction.

Ozgur Akgul1, Huseyin Uyarel2, Hamdi Pusuroglu1, Mehmet Gul1, Nilgun Isiksacan3, Selahattin Turen1, Mehmet Erturk1, Ozgur Surgit1, Mustafa Cetin4, Umit Bulut1, Omer Faruk Baycan1, Nevzat Uslu1.   

Abstract

BACKGROUND: Uric acid (UA) is an independent risk factor for the development of coronary heart disease. Serum UA levels have been correlated with all major forms of death from cardiovascular disease, including acute, subacute, and chronic forms of coronary artery disease (CAD), heart failure, and stroke. However, its value in acute ST-segment elevation myocardial infarction (STEMI) remains unclear. The aim of this study was to evaluate the prognostic value of UA in patients with STEMI undergoing primary percutaneous coronary intervention (PCI).
METHODS: We prospectively enrolled 434 consecutive Turkish STEMI patients (mean age 55.4 ± 12.4 years, 341 male, 93 female) undergoing primary PCI. The study population was divided into tertiles based on admission UA values. The high UA group (n = 143) was defined as a value in the third tertile (> 5.7 mg/dl), and the low UA group (n = 291) included those patients with a value in the lower two tertiles (≤ 5.7 mg/dl). Clinical characteristics, in-hospital and six-month outcomes of primary PCI were analyzed.
RESULTS: Compared to the low UA group, only Killip class > 1 at admission was more prevalent in the high UA group (3.4% vs. 17.5%, p < 0.001, respectively). Higher in-hospital cardiovascular mortality and six-month all-cause mortality rates were observed in the high UA group than in the lower group (12.6% vs. 1.7%, respectively, p < 0.001) and (19.6% vs. 4.1%, respectively, p < 0.001). In Cox multivariate analysis; a high admission UA value (> 5.7 mg/dl) was found to be a powerful independent predictor of six-month all-cause mortality (hazard ratio: 5.57, 95% confidence interval: 1.903-16.3, p = 0.002).
CONCLUSIONS: These results suggest that a high level of UA on admission was associated with increased in-hospital cardiovascular mortality, and six-month all-cause mortality in Turkish patients with STEMI undergoing primary PCI. KEY WORDS: Primary angioplasty; ST elevation myocardial infarction; Uric acid.

Entities:  

Year:  2014        PMID: 27122778      PMCID: PMC4805017     

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  33 in total

1.  The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI.

Authors:  Mahmut Akpek; Mehmet G Kaya; Huseyin Uyarel; Mikail Yarlioglues; Nihat Kalay; Ozgur Gunebakmaz; Orhan Dogdu; Idris Ardic; Deniz Elcik; Omer Sahin; Abdurrahman Oguzhan; Ali Ergin; Charles M Gibson
Journal:  Atherosclerosis       Date:  2011-07-22       Impact factor: 5.162

Review 2.  Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction.

Authors:  Rolf Schröder
Journal:  Circulation       Date:  2004-11-23       Impact factor: 29.690

3.  Assessing kidney function--measured and estimated glomerular filtration rate.

Authors:  Lesley A Stevens; Josef Coresh; Tom Greene; Andrew S Levey
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

Review 4.  Endothelium-dependent modulation of vascular tone and platelet function.

Authors:  U Pohl; R Busse
Journal:  Eur Heart J       Date:  1990-04       Impact factor: 29.983

Review 5.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

6.  The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment.

Authors:  K A Fox; D V Cokkinos; J Deckers; U Keil; A Maggioni; G Steg
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

7.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

8.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

9.  Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study.

Authors:  Leo K Niskanen; David E Laaksonen; Kristiina Nyyssönen; Georg Alfthan; Hanna-Maaria Lakka; Timo A Lakka; Jukka T Salonen
Journal:  Arch Intern Med       Date:  2004-07-26

Review 10.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

View more
  6 in total

1.  Hyperuricemia as an Outcome Predictor in Patients with ST-Segment Elevation Myocardial Infarction: Too Good to be True?

Authors:  Cheng-Wei Liu; Pen-Chih Liao; Yen-Wen Wu; Shin-Rong Ke
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

2.  Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction.

Authors:  Jeng-Feng Lin; Shun-Yi Hsu; Ming-Sheng Teng; Semon Wu; Chien-An Hsieh; Shih-Jung Jang; Chih-Jen Liu; Hsuan-Li Huang; Yu-Lin Ko
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

3.  Hyperuricemia is Associated With 2- and 5-Year Adverse Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.

Authors:  Xiao-Fang Tang; Chen He; Pei Zhu; Che Zhang; Ying Song; Jing-Jing Xu; Yi Yao; Na Xu; Ping Jiang; Lin Jiang; Zhan Gao; Xue-Yan Zhao; Li-Jian Gao; Lei Song; Yue-Jin Yang; Run-Lin Gao; Bo Xu; Jin-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

Review 4.  High serum uric acid levels may increase mortality and major adverse cardiovascular events in patients with acute myocardial infarction.

Authors:  Qiyao Xu; Mei Zhang; Iruni R Abeysekera; Xiaolong Wang
Journal:  Saudi Med J       Date:  2017-06       Impact factor: 1.484

5.  Serum uric acid was an independent predictor of mortality in STsegment elevation myocardial infarction patients with Killip I other than Killip II-IV: Comment on "J Cardiovasc Thorac Res 2016;8:56-60".

Authors:  Cheng-Wei Liu; Tzu-Chiao Lin
Journal:  J Cardiovasc Thorac Res       Date:  2017-03-06

6.  The Prediction of Cardiac Events in Patients with Acute ST Segment Elevation Myocardial Infarction: A Meta-analysis of Serum Uric Acid.

Authors:  Hailong Wang; Jianjun Yang; Jiang Sao; Jianming Zhang; Xiaohua Pang
Journal:  Open Life Sci       Date:  2018-11-09       Impact factor: 0.938

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.